secwatch / observer
FBRX Forte Biosciences, Inc.
CIK 0001419041 48 ready 8-Ks latest August 27, 2026, 4:15 PM ET RSS · JSON
Activity: NORMAL 1 filings / 30d vs 1 baseline
Ready 8-Ks 48
Latest filing August 27, 2026, 4:15 PM ET
Top materiality 1.00
Event mix other_material ×23 · earnings ×13 · other ×5
Sentiment 7 pos · 3 neg · 38 neu
Latest earnings reported 2026-Q1
Executive change recent →
SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for FBRX

Highest-materiality recent filing

Forte Biosciences acquired by argenx for $77.00/share, ~$2.2B; delisting planned

August 27, 2026, 4:15 PM ET M&A materiality 1.00 neutral item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 9.01

Read filing →

Executive changes

Departed

Lawrence Eichenfield

Director
FBRX · Forte Biosciences, Inc.
Effective
2024-09-17
Filed
September 20, 2024, 7:59 PM ET
On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
Appointed

Richard Vincent

Director
FBRX · Forte Biosciences, Inc.
Effective
2024-09-17
Filed
September 20, 2024, 7:59 PM ET
On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
Departed

Donald A. Williams

Director
FBRX · Forte Biosciences, Inc.
Effective
2024-09-17
Filed
September 20, 2024, 7:59 PM ET
On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
Appointed

Shiv Kapoor

Director
FBRX · Forte Biosciences, Inc.
Effective
2024-09-17
Filed
September 20, 2024, 7:59 PM ET
On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
Appointed

David Gryska

Director
FBRX · Forte Biosciences, Inc.
Effective
2023-01-10
Filed
January 12, 2023, 6:59 PM ET
On January 10, 2023, the Board of Directors (the “Board) of the Company, upon recommendation of the Nominating and Governance Committee of the Board, appointed David Gryska, M.B.A. to the Board to fill a vacancy on the Board, effective January 10, 2023.
Departed

Patricia Walker

Director
FBRX · Forte Biosciences, Inc.
Effective
2023-01-06
Filed
January 12, 2023, 6:59 PM ET
On January 6, 2023, Patricia Walker, M.D., Ph.D. notified Forte Biosciences, Inc. (the “Company”) of her resignation as a member of the Board of Directors (the “Board”) of the Company and from all committees of the Board on which she served, in each case effective as of January 6, 2023.
Appointed

Scott Brun

Director
FBRX · Forte Biosciences, Inc.
Effective
2022-11-10
Filed
November 14, 2022, 6:59 PM ET
On November 10, 2022, the Board of Directors (the “Board) of the Company, upon recommendation of the Nominating and Governance Committee of the Board, appointed Scott Brun, M.D. to the Board, effective November 10, 2022.
Role change

Paul A. Wagner

President
FBRX · Forte Biosciences, Inc.
Effective
2022-06-07
Successor
Hubert C. Chen
Filed
June 7, 2022, 7:59 PM ET
the title of President of the Company transitioned from Paul A. Wagner, Ph.D. to Dr. Chen, provided that Dr. Wagner will continue to serve as the Company’s Chief Executive Officer and a member of the Board.
Appointed

Hubert C. Chen

President and Chief Scientific Officer
FBRX · Forte Biosciences, Inc.
Effective
2022-06-07
Filed
June 7, 2022, 7:59 PM ET
On June 5, 2022, the Board of Directors (“Board”) of Forte Biosciences, Inc. (the “Company”) appointed Hubert C. Chen, M.D. to serve as President and Chief Scientific Officer of the Company, effective June 7, 2022.
Appointed

Stephen K. Doberstein

Director
FBRX · Forte Biosciences, Inc.
Effective
2022-05-12
Filed
May 16, 2022, 7:59 PM ET
Appointment of Director On May 12, 2022, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, appointed Stephen K. Doberstein, Ph.D. to the Board, effective May 12, 2022.
Appointed

Barbara K. Finck, M.D.

Director
FBRX · Forte Biosciences, Inc.
Effective
2022-03-16
Filed
March 18, 2022, 7:59 PM ET
appointed Barbara K. Finck, M.D. to the Board, effective March 16, 2022.

Earnings & guidance

2026-Q1 EPS reported -$1.24 filing →

Materiality & sentiment trend

Max materiality 1.00 · Median 0.60 · Most common event other_material

7 positive 3 negative 38 neutral

source · FBRX on sec.gov